Your browser doesn't support javascript.
loading
Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study.
Nakamura, Yoshiaki; Mizuno, Nobumasa; Sunakawa, Yu; Canon, Jean-Luc; Galsky, Matthew D; Hamilton, Erika; Hayashi, Hidetoshi; Jerusalem, Guy; Kim, Seung Tae; Lee, Keun-Wook; Kankeu Fonkoua, Lionel Aurelien; Monk, Bradley J; Nguyen, Danny; Oh, Do-Youn; Okines, Alicia; O'Malley, David M; Pohlmann, Paula; Reck, Martin; Shin, Sang Joon; Sudo, Kazuki; Takahashi, Shunji; Van Marcke, Cedric; Yu, Evan Y; Groisberg, Roman; Ramos, Jorge; Tan, Sherry; Stinchcombe, Thomas E; Bekaii-Saab, Tanios.
Affiliation
  • Nakamura Y; National Cancer Center Hospital East, Kashiwa, Japan.
  • Mizuno N; Aichi Cancer Center Hospital, Nagoya, Japan.
  • Sunakawa Y; St Marianna University Hospital, Kawasaki, Japan.
  • Canon JL; Grand Hospital de Charleroi, Charleroi, Belgium.
  • Galsky MD; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.
  • Hamilton E; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN.
  • Hayashi H; Kindai University Hospital, Osakasayama, Japan.
  • Jerusalem G; CHU de Liege and Liege University, Liege, Belgium.
  • Kim ST; Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea.
  • Lee KW; Seoul National University College of Medicine and Seoul National University Bundang Hospital, Seongnam, South Korea.
  • Kankeu Fonkoua LA; Mayo Clinic Rochester, Rochester, MN.
  • Monk BJ; HonorHealth Research Institute, University of Arizona, Creighton University, Phoenix, AZ.
  • Nguyen D; City of Hope National Medical Center, Duarte, CA.
  • Oh DY; Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Integrated Major in Innovative Medical Science, Seoul National University Graduate School, Seoul, South Korea.
  • Okines A; The Royal Marsden NHS Foundation Trust, London, UK.
  • O'Malley DM; The Ohio State University & James Comprehensive Cancer Center, Columbus, OH.
  • Pohlmann P; MD Anderson Cancer Center, Houston, TX.
  • Reck M; Department of Thoracic Oncology, Airway Research Center North, Germany Center for Lung Disease, Grosshansdorf, Germany.
  • Shin SJ; Severance Hospital, Yonsei University Health System, Seoul, South Korea.
  • Sudo K; National Cancer Center, Tokyo, Japan.
  • Takahashi S; Cancer Institute Hospital of JFCR, Tokyo, Japan.
  • Van Marcke C; Cliniques Universitaires Saint-Luc, Brussels, Belgium.
  • Yu EY; Fred Hutchinson Cancer Center/University of Washington, Seattle, WA.
  • Groisberg R; Merck & Co, Inc, Rahway, NJ.
  • Ramos J; Seagen Inc, Bothell, WA.
  • Tan S; Seagen Inc, Bothell, WA.
  • Stinchcombe TE; Duke Cancer Institute, Durham, NC.
  • Bekaii-Saab T; Mayo Clinic Scottsdale, Scottsdale, AZ.
J Clin Oncol ; 41(36): 5569-5578, 2023 Dec 20.
Article in En | MEDLINE | ID: mdl-37751561
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antibodies, Monoclonal, Humanized / Neoplasms Type of study: Prognostic_studies Limits: Humans Language: En Journal: J Clin Oncol Year: 2023 Document type: Article Affiliation country: Japón Country of publication: Estados Unidos
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antibodies, Monoclonal, Humanized / Neoplasms Type of study: Prognostic_studies Limits: Humans Language: En Journal: J Clin Oncol Year: 2023 Document type: Article Affiliation country: Japón Country of publication: Estados Unidos